A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design

Peer Review reports

Original Submission
20 May 2014	Submitted	Original manuscript
24 Jun 2014	Reviewed	Reviewer Report - Hiddo Heerspink
31 Jul 2014	Author responded	Author comments - Hajimu Kurumatani
Resubmission - Version 2
31 Jul 2014	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
22 Aug 2014	Author responded	Author comments - Hajimu Kurumatani
Resubmission - Version 4
22 Aug 2014	Submitted	Manuscript version 4
Publishing
28 Aug 2014	Editorially accepted
19 Sep 2014	Article published	10.1186/1471-2369-15-153

Back to article page